Mendoza ZV, Ramírez RC, González VGA, Espinosa BAE, Peña GJF, Hernández GI, Mercado M

Language: Spanish
References: 23
Page: 13-20
PDF size: 103.46 Kb.

ABSTRACT

Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder. It is characterized by chronic and excessive secretion of parathyroid hormone (PTH) originating from one or more parathyroid glands. The PHPT is associated with hypercalcemia and elevated levels of PTH. The incidence is variable and it is more frequent in post menopausic women (3:1). In the last decades the diagnosis of asymptomatic PHPT has increased since the introduction of automatized determinations of serum calcium. The symptomatology is related with the levels of calcium and PTH as well as the duration of the disease. Surgery is the primary option in treatment. It is important to assess the surgical criteria in asymptomatic patients. The successful treatment of this disease depends on a highly specialized team of parathyroid surgeons. Material and methods: We reviewed the clinical and biochemical background of patients that were subject to parathyroidectomy from January 1998 to December 2009 in our medical center. We analyzed the clinical and laboratory data, the final histopathologic diagnosis, and the surgery outcome. Results: 145 patients were included, with an average age of 53.2 years (± 13), including 25 men and 120 women. The greatest frequency of PHPT was observed in patients between 40 and 69 years of age. The average calcium level at diagnosis was 11.8 mg/dL (± 1.34) and the level of PTH was of 316.5 (50-4627 pg/mL). The histopathology diagnosis was: adenoma in 110 (76.6%), hyperplasia in 28 (19.3 %) and carcinoma in 6 (4.1%) patients. The disease was considered to be cured in 138 patients (95.2%) after the first surgery.Conclusions: PHPT is a surgically curable disease, it is necessary to confirm the diagnosis and decide the surgical treatment in accordance with the established criteria even if the disease is asymptomatic.

REFERENCES

1. Bilezikian JP, Silverger SJ. Clinical spectrum of primary hyperparathyroidism. Rev Endocrinol Metabol Dis 2000; 1: 237-245.

2. Silverger SJ. Natural history of primary hyperparathyroidism. Endocrinol and Metabolism Clin North Am 2000; 29: 451-64.

3. Mark SJ. Hyperparathyroidism and hypoparathyroid disorders. N Engl J Med 2000; 343: 1863-75.

4. DeLellis RA, Mazzaglia P, Mangray S. Primary hyperparathyroidism. A current perspective. Arch Pathol Lab Med 2008; 132: 1251-1262.

5. Iglesias P, Díez JJ. Current treatment in the management of patients with primary hyperparathyroidism. Postgrad Med J 2009; 85: 15-22.

6. Bilezikian JP, Silverberg SJ. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004; 350: 1746-1751.

7. Bolland MJ, Grey BA, Gamble GD, Reid IR. Association between Primary hyperparathyroidism and increased body weight: A Meta-analysis. J Clin Endocrinol Metab 2005; 90: 1525-1530.

8. Kamycheva E, Sundsfjord J, Jorde R. Serum parathyroid hormone level is associated with body mass index. The 5th Tromso study. Eu J Endocrinol 2004; 151: 167-17.

9. Pasieka JL, Parsons LL, Demeure MJ et al. Patient based surgical outcome tool demonstrating alleviation os symptoms following parathyroidectomy in patients with primary hyperparathyroidism. World J Surg 2002; 26: 942-949.

10. Udelsman R, Pasieka JL, Sturgeon C, Young JEM, Clark OH. Surgery asymptomac primary hyperparathyroidism. Proceeding of the third international workshop. J Clin Endocrinol Metab 2009; 94: 366-372.

11. Silverberg SJ, Lewiecki EM, Mosekilde L et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009; 94: 351-365.

12. Potts JT Jr, Fradkin JE, Aurbach GD, Bilezikian JP, Raisz LG, eds Proceedings of the NIH Consensus Development Conference on Diagnosis and management of Asymptomatic Primary Hyperparathyroidism, Bethesda, Maryland, October 29-31, 1990. J Bone Miner Res 1991; 6(Suppl 2): S1-166.

13. Bilezikian JP, Potts JT, Fuleihan EH et al. Summary statement from a workshop an asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab 2002; 87: 5353-61.

14. Bilezikian JP, Khan AA, Potts JT, on behalf of the third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. Management for the Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. J Clin Endocrinol Metab 2009; 94: 335-339.

15. Irvin GL III, Sfakianakis G, Yeung L et al. Ambulatory parathyroidectomy for primary hyperparathyroidism. Arch Surg 1996; 131: 1074-78.

16. Ollila DW, Caudle SA, Cance WG, Kim HJ, Cusack JC, Swasey JE, Calvo BF. Successful minimally invasive parathyroidectomy for primary hyperparathyroidism without using intraoperative parathyroid hormone assays. Am J Surg 2006; 191: 52-56.

17. Gallender GG, Rich TA, Perrier ND. Multiple endocrine neoplasia syndromes. Surg Clin N Am 2008; 88: 863-895.

18. Undelsman R. Six hundred fifty six consecutive explorations for primary hyperparathyroidism. Ann Surg 2002; 235: 665-670.

19. Bergenfelz A, Lndblom P, Tibblin S et al. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg 2002; 236: 543-51.

20. Ozbey N, Erbil Y, Ademoglu E et al. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg 2006; 30: 321-326.

21. Silverberg SJ. Vitamin D deficiency and primary hyperthyroidism. J Bone Miner Res 2007; 22: 100-104.

22. Parks J, CoerF, Favus M. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140: 1479.

23. Mendoza V, Hernandez A, Marquez MA, Delgadillo M, Peña J, Mercado M. Primary hyperparathyroidism due to parathyroid carcinoma. Arch Med Res 1997; 28: 303-306.